Drug-resistant tuberculosis: an experience from Qatar

ABSTRACT This study was conducted to evaluate the characteristics, treatment outcome and risk factors associated with 223 drug-resistant tuberculosis (DR-TB) cases in the State of Qatar. A descriptive records-based retrospective study was conducted on patients registered at Communicable Disease Centre (CDC), Qatar to all consecutive microbiologically confirmed tuberculosis cases for the period January 2010 – March 2015. Demographic, clinical data, drug-resistance pattern of isolated mycobacteria and treatment outcome was assessed for the patient who completed their treatment in Qatar. Of 3301 patients with positive M. tuberculosis culture were analyzed; 223 (6.7%) were resistant to at least one drug. The overall prevalence of multi-d rug resistant TB (MDR-TB) was 1.2% (n = 38) of patients. A former resident of Indian sub contents was the most common demographic characteristic observed (64.1%). The outcome of treatment was assessed for 85 resistant cases with follow-up after completion of treatment. Cure and relapse rates were 97.6%, and 2.4%, respectively. Drug-resistant TB in Qatar is influenced by migration where the patients were probably infected. Rapid sputum sampling performed in the early stages of the disease, patient isolation, and drug-susceptibility testing should be the standard of care.

[1]  S. Mahmoudi,et al.  First-Line Anti-Tubercular Drug Resistance of Mycobacterium tuberculosis in IRAN: A Systematic Review , 2016, Front. Microbiol..

[2]  W. Han,et al.  Determinants of multidrug-resistant tuberculosis in Henan province in China: a case control study , 2015, BMC Public Health.

[3]  Z. Mor,et al.  Drug-resistant tuberculosis in Israel: risk factors and treatment outcomes. , 2014, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[4]  R. Mandal,et al.  Prevalence of drug resistance in clinical isolates of tuberculosis from GCC: a literature review from January 2002 to March 2013. , 2014, Journal of infection in developing countries.

[5]  Nalin Rastogi,et al.  A study of Mycobacterium tuberculosis genotypic diversity & drug resistance mutations in Varanasi, north India , 2014, The Indian journal of medical research.

[6]  E. Çakır,et al.  Demographic and microbial characteristics and drug resistance of childhood tuberculosis in Istanbul: analysis of 1,541 cases. , 2014, Journal of infection in developing countries.

[7]  Z. Memish,et al.  Epidemiology of Antituberculosis Drug Resistance in Saudi Arabia: Findings of the First National Survey , 2013, Antimicrobial Agents and Chemotherapy.

[8]  D. Falzon,et al.  Modernizing Surveillance of Antituberculosis Drug Resistance: From Special Surveys to Routine Testing , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  K. Kam,et al.  Epidemiology of antituberculosis drug resistance 2002–07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance , 2009, The Lancet.

[10]  S. Mitarai,et al.  Nationwide survey on the prevalence of anti-tuberculosis drug resistance in the Republic of Yemen, 2004. , 2007, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[11]  A. Faustini,et al.  Risk factors for multidrug resistant tuberculosis in Europe: a systematic review , 2005, Thorax.

[12]  M. Jesudason,et al.  Clinical characteristics and treatment response among patients with multidrug-resistant tuberculosis: a retrospective study. , 2003, The Indian journal of chest diseases & allied sciences.

[13]  M. Almarri Pattern of mycobacterial resistance to four anti-tuberculosis drugs in pulmonary tuberculosis patients in the state of Qatar after the implementation of DOTS and a limited expatriate screening programme. , 2001, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[14]  J. Robert,et al.  Surveillance of Mycobacterium tuberculosis drug resistance in France, 1995-1997. AZAY Mycobacteria Study Group. , 2000, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[15]  M. A. Marri,et al.  The Time of Reactivation of Tuberculosis in Expatriates in the State of Qatar , 2006 .

[16]  D. Mitchison Drug resistance in mycobacteria. , 1984, British medical bulletin.